Clinical Trial

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This trial is investigating an intravenous (IV) medication called 9-ING-41 in combination with chemotherapy (carboplatin) for the treatment of advanced salivary gland cancers. The names of the study drug(s) involved in this study are: * 9-ING-41 (a GSK-3β inhibitor) * Carboplatin chemotherapy
Protocol Amendment History 2 changes
critical Primary endpoint(s) modified 2026-08-08
minor Trial arms changed: 1 -> 2 2026-08-08
Trial Details
NCT Number NCT05010629
Lead Sponsor Glenn J. Hanna
Collaborators: Actuate Therapeutics Inc.
Conditions Salivary Gland Cancer, Recurrent Salivary Gland Cancer, Metastatic Cancer, Adenoid Cystic Carcinoma
Enrollment 32 participants
Start Date 2021-09-17
Primary Completion 2025-02-14 (estimated)
Study Completion 2027-04-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-07